The company leverages its proprietary Stem-SPACE™ platform technology to differentiate specific, highly potent immune cell states from stem cells and provide long-lasting benefits to patients. With a vision to democratize access to live cell-based medicines for all patients, Cell BioEngines aims to turn all cancers into curable diseases through its pre-clinical stage immunotherapy products and product candidates. Its revolutionary science includes single cell discoveries from Harvard Medical School and in-licensed manufacturing process technology from Icahn School of Medicine at Mount Sinai. For more information, visit www.cellbioengines.com and follow us on www.twitter.com/cell_bioengines.